Related Experiment Videos
Pharmacogenetics and pediatric cancer
Lisa Bomgaars1, Howard L McLeod
1Department of Medicine, Baylor College of Medicine, Houston, Texas 77030, USA. lboomgaars@txccc.org
Cancer Journal (Sudbury, Mass.)
|October 4, 2005
Summary
Genetic variations impact childhood cancer drug toxicity. Understanding these genetic factors can help personalize treatment, reducing side effects and improving outcomes for young patients undergoing chemotherapy.
Area of Science:
- Pharmacogenomics
- Oncology
- Toxicology
Background:
- Advances in childhood cancer therapy necessitate strategies to mitigate chemotherapy's systemic toxicities.
- Genetic variations in drug metabolism pathways significantly influence anticancer agent toxicity.
- While adult pharmacogenetic associations are established, pediatric data remain less defined.
Purpose of the Study:
- To review the impact of genetic mutations in drug metabolism on anticancer agent toxicity in children.
- To explore the role of specific genetic polymorphisms (MTHFR, TYMS, TPMT, UGT1A1) in pediatric drug toxicity.
Main Methods:
- Literature review focusing on genetic polymorphisms and their association with drug toxicity in pediatric oncology.
- Analysis of existing studies on MTHFR, TYMS, TPMT, and UGT1A1 gene variants in relation to chemotherapy side effects.
Main Results:
- Genetic polymorphisms in MTHFR, TYMS, TPMT, and UGT1A1 are implicated in influencing drug toxicity in children.
- Associations between specific polymorphisms and toxicity are less defined in pediatric populations compared to adults.
Conclusions:
- Understanding pharmacogenetic determinants is crucial for identifying children at high risk of chemotherapy toxicity.
- Personalized dosing based on genetic profiles can optimize treatment efficacy while minimizing toxic risks in pediatric cancer patients.